Top Markets
#1 Siren Siren +38.07%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.61%
#3 RedStone RedStone +20.14%
#4 Verus Coin Verus Coin +18.07%
#5 Cysic Cysic +17.41%
#6 Ocean Protocol Ocean Protocol +16.25%
#7 Perle Perle +14.21%
#8 KUB Coin KUB Coin +13.13%
#9 OpenEden OpenEden +12.87%
#10 Arowana Arowana +12.55%
Coin of the day
Siren Siren
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Intensity Therapeutics, Inc. Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc.

INTS
Kedudukan dalam Saham #32095
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical... Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.
Harga Saham
$4.12
Disegerakkan terakhir: 2026-08-17
Modal Pasaran
$11.14M
Perubahan (1 hari)
4.04%
Perubahan (1 tahun)
-45.79%
Negara
US
Perdagangan Intensity Therapeutics, Inc. (INTS)

Kategori

Healthcare
Nisbah P/E bagi Intensity Therapeutics, Inc. (INTS)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Intensity Therapeutics, Inc., nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Intensity Therapeutics, Inc. dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.